Conclusion of Non-Exclusive Drug Discount Agreements pursuant to § 130a Para. 8 SGB V via an Open-House Model for the Active Ingredient Icatibant (ATC Code B06AC02)

This tender, originating from Germany, concerns the establishment of non-exclusive drug discount agreements for the active ingredient Icatibant (ATC code B06AC02) under Section 130a, Paragraph 8 of the German Social Code Book V (SGB V). The procurement will utilize an 'Open-House' model, which allows eligible pharmaceutical manufacturers to join the agreement during its term. The contracting authority seeks to secure cost-effective access to Icatibant, a medication used for hereditary angioedema, for the German statutory health insurance system. The agreements will govern the supply and pricing of the drug. This procurement strategy aims to foster competition among suppliers and ensure favorable pricing and availability for this essential medicine. The Open-House model provides flexibility for manufacturers to participate while ensuring the health insurance system benefits from competitive terms over the agreement's duration.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals and Health Financing. Located in Germany, Europe, this opportunity is open to firms and consortiums. Proposals must be submitted before May 31, 2028.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.